🏢 官网IRMIRMCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:01:00·⟳ 抓取 04:03:38 +2m38s·⚡ 决策 07-30 04:04:23 +45s·89.8 天前
Mirum Pharmaceuticals宣布将于8月5日披露二季度业绩并召开电话会
本次只是公司例行预告财报披露和电话会时间，没有披露业绩数据、指引变化、药品进展或监管结果。
📄 原文MIRM↗ 原文
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, toda…
不做 Mirum Pharmaceuticals（MIRM.US）
例行财报日期和电话会通知，无业绩数据、指引修正、药品审批或商业化进展，不形成同向交易催化。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-29 · 扩散 low · price-in 风险 low ↗
关键理由
- 本次只是公司例行预告财报披露和电话会时间，没有披露业绩数据、指引变化、药品进展或监管结果。
主要风险
- 真正可交易信息需等待2026-08-05二季度业绩、指引或管线更新落地。
原文全文
展开原文 · 2,283 字
FOSTER CITY, Calif.--(BUSINESS WIRE)--
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report second quarter 2026 financial results on August 5, 2026. Mirum will also host a conference call to discuss the second quarter 2026 financial results and recent corporate progress.
Conference call details:
Wednesday, August 5, 2026
4:30 p.m. ET / 1:30 p.m. PT
Dial-In:
US/Toll-Free: + 1 833 461 5787
International: +1 585 542 9983
Access Code: 789239699
You may also access the call via webcast by visiting the
Investors
section of Mirum’s corporate website. The archived webcast will be available for replay.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at
www.mirumpharma.com
and follow Mirum on
Facebook
,
LinkedIn
,
Instagram
and
X
.
Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Meredith Kiernan
media@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report second quarter 2026 financial results on August 5, 2026. Mirum will also host a conference call to discuss the second quarter 2026 financial results and recent corporate progress.
Conference call details:
Wednesday, August 5, 2026
4:30 p.m. ET / 1:30 p.m. PT
Dial-In:
US/Toll-Free: + 1 833 461 5787
International: +1 585 542 9983
Access Code: 789239699
You may also access the call via webcast by visiting the
Investors
section of Mirum’s corporate website. The archived webcast will be available for replay.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at
www.mirumpharma.com
and follow Mirum on
,
,
and
X
.
Investor Contact:
Andrew McKibben
ir@mirumpharma.com
Media Contact:
Meredith Kiernan
media@mirumpharma.com
Source: Mirum Pharmaceuticals, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。